• Explore /
  • Poster
  • / Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.

Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.

Abstract Poster

Authors

null

Keun-Wook Lee

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea, Republic of (South);

Keun-Wook Lee , Hark Kyun Kim , Min-Hee Ryu , Dae Young Zang , Ji-Won Kim , Bum Jun Kim , Hyung-Don Kim , Jin Won Kim , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03751761

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 401)

DOI

10.1200/JCO.2023.41.4_suppl.401

Abstract #

401

Poster Bd #

H4

Abstract Disclosures

Similar Posters

First Author: David Tougeron

First Author: Timothy Jay Price

First Author: Chee Khoon Lee

First Author: Michal Sarfaty